12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

Core Elements of ED Antimicrobial Stewardship

The emergency department is the main gateway for acute hospital admissions, and many inpatient antimicrobial courses begin with the first dose given in the ED. Because the ED environment is characterized by rapid turnover, diagnostic uncertainty, and high acuity, antimicrobial stewardship programs (ASPs) face unique operational demands.

ED Stewardship Interventions

1. Indication-Specific CPOE Order Sets: Computerized provider order entry (CPOE) order sets structured by specific clinical syndrome (e.g., severe CAP, pyelonephritis, non-purulent cellulitis, intra-abdominal sepsis) rather than generic drug lists. These order sets integrate standardized renal dosing, weight-based loading regimens, and default duration limits.
2. Pharmacokinetic / Pharmacodynamic (PK/PD) Optimization: Clinical emergency pharmacists implement evidence-based dosing protocols at the point of care:
   • Extended-Infusion Beta-Lactams: Administering piperacillin-tazobactam as an extended 4-hour infusion or cefepime over 3-4 hours maximizes the time that unbound serum drug concentrations exceed the minimum inhibitory concentration (fT > MIC), which correlates directly with clinical cure in Gram-negative sepsis.
   • Weight-Based Vancomycin Loading: Administering 20 to 35 mg/kg IV (maximum 2,000-3,000 mg) in critically ill patients rapidly achieves therapeutic serum concentrations within the initial dosing interval.
3. Discharge Stewardship: Up to 30% to 50% of outpatient antibiotic prescriptions written in the ED contain errors in drug selection, dose, or duration. Key discharge stewardship initiatives include:
   • Enforcing short, guideline-concordant durations: 3 days of TMP-SMX or 5 days of nitrofurantoin for uncomplicated cystitis; 5 days of beta-lactam therapy for uncomplicated cellulitis or resolving CAP.
   • Eliminating Inappropriate Fluoroquinolone Prescriptions: Fluoroquinolones (ciprofloxacin, levofloxacin) carry an FDA boxed warning for disabling, potentially irreversible adverse effects: tendinitis and tendon rupture (particularly the Achilles tendon), peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis. Separate (non-boxed) warnings cover aortic aneurysm and dissection, dysglycemia including hypoglycemic coma, and Clostridioides difficile infection. Fluoroquinolones should be restricted to infections where no safer alternatives exist.

---

Rapid Blood Culture Identification & Diagnostic Integration

Traditional phenotypic blood culture workflows require 24 to 48 hours for blood culture bottles to flag positive, followed by subculturing, Gram staining, and an additional 24 to 48 hours for automated identification and antimicrobial susceptibility testing (AST). Total turnaround time ranges from 48 to 96 hours.

Rapid Molecular Platforms

• Multiplex PCR Panels (e.g., BioFire FilmArray BCID2, GenMark ePlex, Luminex Verigene): Directly amplify and detect bacterial and fungal pathogens and critical resistance determinants directly from positive blood culture broth within 1 to 2 hours of bottle positivity.
• MALDI-TOF Mass Spectrometry: Identifies bacterial species within minutes using matrix-assisted laser desorption/ionization time-of-flight spectral fingerprinting from early subculture pellets.

Actionable Resistance Markers & ED Stewardship Decision Tree

                  RAPID BLOOD CULTURE IDENTIFICATION (BCID) TARGETS
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Gram-Positive Targets & Resistance Determinants                             │
  │ • mecA / mecC (S. aureus) ──► MRSA (PBP2a) ──► Continue Vanc/Dap; Optimize  │
  │ • No mecA (S. aureus)     ──► MSSA         ──► De-escalate to Cefazolin 2g  │
  │ • vanA / vanB (E. faecium)──► VRE (D-Ala-Lac)► Switch to Daptomycin/Linezolid│
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ Gram-Negative Targets & Resistance Determinants                             │
  │ • blaCTX-M                ──► ESBL         ──► Carbapenem (Meropenem 1g)    │
  │ • blaKPC                  ──► Carbapenemase──► Ceftazidime-avibactam / Vab  │
  │ • blaNDM / blaVIM         ──► Metallo-BL   ──► Cefiderocol OR CZA + AZT     │
  └─────────────────────────────────────────────────────────────────────────────┘

---

Procalcitonin (PCT) in Lower Respiratory Tract Infections

Procalcitonin (PCT) is a 116-amino acid peptide prohormone. Under non-infectious physiological conditions, it is produced in the neuroendocrine C-cells of the thyroid gland, where it is cleaved into calcitonin with undetectable serum levels (<0.05 mcg/L).

Biology of the Host Response

• Bacterial Stimulation: In response to systemic bacterial infection, bacterial endotoxin (lipopolysaccharide) and pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) induce ubiquitous transcription of the CALC-1 gene in all parenchymal tissues (liver, lung, kidney, adipose). Large quantities of procalcitonin are released into circulation, detectable within 2 to 4 hours and peaking at 12 to 24 hours.
• Viral Suppression: During systemic viral infections, host T-cells and monocytes secrete interferon-gamma (IFN-gamma), which selectively blocks and down-regulates CALC-1 gene transcription. Consequently, procalcitonin levels remain low or undetectable during pure viral respiratory infections (e.g., influenza, SARS-CoV-2, RSV, human metapneumovirus).

Clinical Decision Algorithm in LRTIs

Clinical Limitations & Confounding Factors

• False-Positive Elevations (Non-Infectious Sepsis Mimics): Severe non-infectious physiological trauma triggers massive parenchymal cytokine release, producing elevated PCT in the absence of bacterial infection. Common false-positive etiologies include: massive mechanical trauma, extensive burn injury, post-cardiac arrest resuscitation (post-resuscitation syndrome), acute ischemic bowel, severe pancreatitis, end-stage renal disease (ESRD on hemodialysis due to decreased renal clearance), and medullary thyroid carcinoma.
• False-Negative Results: Early presentation (<4-6 hours from symptom onset; kinetics require 6-12 hours for peak synthesis), localized non-invasive infections (small empyema, localized cutaneous abscess), and atypical intracellular pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae).

---

Post-Discharge Culture and Susceptibility Callback Programs

Urine, blood, sputum, and wound cultures obtained in the emergency department typically finalize 24 to 72 hours after collection, long after the patient has been discharged home. Without systematic follow-up, discordant antimicrobial therapy leads to treatment failures, preventable hospital readmissions, and recurrent ED visits.

Pharmacist-Led Callback Architecture

Emergency medicine pharmacists are uniquely positioned to manage culture callback workflows using electronic health record surveillance queues. The daily callback protocol involves three core review steps:

1. Evaluation of Culture Results: Review finalized organism identification and in vitro susceptibility profile.
2. Evaluation of Prescribed Empiric Regimen: Determine whether the prescribed discharge antibiotic is concordant (susceptible), discordant (resistant), or suboptimal (overly broad or subtherapeutic).
3. Patient Assessment & Intervention:
   • Bug-Drug Discordance (Resistance): Contact the patient via telephone. If the patient is asymptomatic and clinically resolved, re-evaluation may be deferred depending on the clinical syndrome; if symptoms persist or worsen, change therapy via an established collaborative practice agreement (CPA) to a targeted, narrow-spectrum agent and electronic-prescribe to their outpatient pharmacy. Instruct the patient to return to the ED if fevers, rigors, flank pain, or altered mentation develop.
   • Positive Blood Cultures: Any discharged patient with a confirmed pathogenic positive blood culture (e.g., Staphylococcus aureus, Streptococcus pneumoniae, Gram-negative bacilli) represents a clinical emergency requiring immediate direct contact and routing back to the ED for repeat blood cultures, echocardiography, source identification, and IV antimicrobial therapy.
   • Asymptomatic Bacteriuria (ASB) Interception: Intercepting and discontinuing unnecessary discharge antibiotics in elderly patients with positive urine cultures who presented for non-infectious complaints (e.g., mechanical falls, chronic confusion) and lack true lower urinary tract symptoms.

---

Antibiotic Allergies in the ED: Penicillin Allergy De-Labeling

Approximately 10% of the United States population reports a penicillin allergy in their electronic health record. However, extensive clinical and immunological studies show that over 90% to 95% of these patients are not truly allergic when subjected to formal testing. Many reported reactions are either non-allergic adverse effects (e.g., childhood nausea, headache, viral exanthem) or represent IgE antibodies that have naturally waned over time (IgE-mediated sensitivity decays by approximately 10% to 20% per year; >80% lose sensitivity after 10 years).

The Clinical Cost of False Allergy Labels

Patients carrying an unverified penicillin allergy label receive significantly more second-line, broad-spectrum agents (vancomycin, fluoroquinolones, clindamycin, aminoglycosides), resulting in:

• A 30% higher risk of Clostridioides difficile colitis
• Higher rates of surgical site infections
• Increased colonization with MRSA and VRE
• Higher rates of acute kidney injury from vancomycin and aminoglycosides
• Longer lengths of stay and elevated healthcare expenditures

Immunological Cross-Reactivity: R1 Side Chains vs. The Beta-Lactam Ring

Historical dogma taught that penicillins exhibit a 10% cross-reactivity rate across all cephalosporins. This historic estimate was derived from flawed 1960s literature, where early cephalosporin lots were heavily contaminated with trace penicillin during manufacture.

Modern immunological evidence confirms that true IgE-mediated cross-reactivity is determined by structural homology of the R1 side chain, NOT the core four-membered beta-lactam ring:

                      BETA-LACTAM CORE vs. R1 SIDE-CHAIN HOMOLOGY
         Penicillin Core                    Cephalosporin Core
       ┌────────────────┐                  ┌────────────────┐
    R1─┤   β-Lactam     │               R1─┤   β-Lactam     │─R2
       │ 5-Member Ring  │                  │ 6-Member Ring  │
       └────────────────┘                  └────────────────┘
         Thiazolidine                         Dihydrothiazine

• First-Generation Cephalosporins:
  • Cefazolin: Possesses a unique dihydro-thiadiazole R1 side chain that shares zero structural homology with penicillin, ampicillin, or amoxicillin. True cross-reactivity between penicillin and cefazolin is virtually 0%. Cefazolin is safe to administer in almost all penicillin-allergic patients without history of severe cutaneous adverse reactions.
  • Cephalexin & Cefadroxil: Share identical or near-identical R1 side chains with ampicillin and amoxicillin, respectively. Cross-reactivity between amoxicillin and cephalexin is approximately 2% to 3%.
• Third- and Fourth-Generation Cephalosporins (Ceftriaxone, Cefotaxime, Cefepime):
  • Possess an oxyimino aminothiazolyl R1 side chain that is completely structurally distinct from penicillin and aminopenicillins.
  • True cross-reactivity between penicillin and ceftriaxone, cefotaxime, or cefepime is <1% to 2% (comparable to baseline drug reaction rates in unallergic populations).
• Carbapenems (Meropenem, Ertapenem, Imipenem):
  • Cross-reactivity between penicillin and carbapenems is <1%.
• Monobactams (Aztreonam):
  • Aztreonam has a standalone monocyclic beta-lactam ring and exhibits zero cross-reactivity with all penicillins and cephalosporins EXCEPT Ceftazidime (aztreonam and ceftazidime share an identical R1 side chain).

Penicillin Allergy Cross-Reactivity Matrix

The PEN-FAST Decision Tool for ED De-Labeling

The PEN-FAST score is a validated point-of-care clinical decision rule developed to rapidly risk-stratify reported penicillin allergies in adult patients:

• P (Penicillin allergy within past 5 years): 2 points
• E (Anaphylaxis or Angioedema, OR Severe Cutaneous Adverse Reaction [SCAR: SJS/TEN, DRESS]): 2 points
• N (Treatment required for allergy episode [epinephrine, steroids, antihistamines, ED visit]): 1 point

PEN-FAST Clinical Risk Scoring

• Score 0: Very low risk (<1% probability of true IgE-mediated allergy)
• Score 1 to 2: Low risk (<5% probability of true allergy)
• Score ≥3: Moderate to high risk (≥20% probability of true allergy)